536 related articles for article (PubMed ID: 9591765)
1. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy.
Thomas CV; Coker ML; Zellner JL; Handy JR; Crumbley AJ; Spinale FG
Circulation; 1998 May; 97(17):1708-15. PubMed ID: 9591765
[TBL] [Abstract][Full Text] [Related]
2. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure.
Spinale FG; Coker ML; Heung LJ; Bond BR; Gunasinghe HR; Etoh T; Goldberg AT; Zellner JL; Crumbley AJ
Circulation; 2000 Oct; 102(16):1944-9. PubMed ID: 11034943
[TBL] [Abstract][Full Text] [Related]
3. Defects in matrix metalloproteinase inhibitory stoichiometry and selective MMP induction in patients with nonischemic or ischemic dilated cardiomyopathy.
Coker ML; Zellner JL; Crumbley AJ; Spinale FG
Ann N Y Acad Sci; 1999 Jun; 878():559-62. PubMed ID: 10415772
[No Abstract] [Full Text] [Related]
4. Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts.
Tyagi SC; Campbell SE; Reddy HK; Tjahja E; Voelker DJ
Mol Cell Biochem; 1996 Feb; 155(1):13-21. PubMed ID: 8717434
[TBL] [Abstract][Full Text] [Related]
5. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat.
Peterson JT; Li H; Dillon L; Bryant JW
Cardiovasc Res; 2000 May; 46(2):307-15. PubMed ID: 10773235
[TBL] [Abstract][Full Text] [Related]
6. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation.
Rouet-Benzineb P; Buhler JM; Dreyfus P; Delcourt A; Dorent R; Perennec J; Crozatier B; Harf A; Lafuma C
Eur J Heart Fail; 1999 Dec; 1(4):337-52. PubMed ID: 10937947
[TBL] [Abstract][Full Text] [Related]
7. Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum.
Vaillant C; Didier-Bazès M; Hutter A; Belin MF; Thomasset N
J Neurosci; 1999 Jun; 19(12):4994-5004. PubMed ID: 10366632
[TBL] [Abstract][Full Text] [Related]
8. Predominance of MMP-1 and MMP-2 in epiretinal and subretinal membranes of proliferative vitreoretinopathy.
Webster L; Chignell AH; Limb GA
Exp Eye Res; 1999 Jan; 68(1):91-8. PubMed ID: 9986746
[TBL] [Abstract][Full Text] [Related]
9. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis.
Kossakowska AE; Edwards DR; Lee SS; Urbanski LS; Stabbler AL; Zhang CL; Phillips BW; Zhang Y; Urbanski SJ
Am J Pathol; 1998 Dec; 153(6):1895-902. PubMed ID: 9846979
[TBL] [Abstract][Full Text] [Related]
10. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy.
Tyagi SC; Kumar SG; Haas SJ; Reddy HK; Voelker DJ; Hayden MR; Demmy TL; Schmaltz RA; Curtis JJ
J Mol Cell Cardiol; 1996 Jul; 28(7):1415-28. PubMed ID: 8841929
[TBL] [Abstract][Full Text] [Related]
11. Collagenase-1, stromelysin-1 and 92 kDa gelatinase are associated with tumor necrosis factor-alpha induced morphological change of human endothelial cells in vitro.
Nelimarkka LO; Nikkari ST; Ravanti LS; Kähäri VM; Järveläinen HT
Matrix Biol; 1998 Aug; 17(4):293-304. PubMed ID: 9749945
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy.
Schwartzkopff B; Fassbach M; Pelzer B; Brehm M; Strauer BE
Eur J Heart Fail; 2002 Aug; 4(4):439-4. PubMed ID: 12167381
[TBL] [Abstract][Full Text] [Related]
13. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat.
Knittel T; Mehde M; Grundmann A; Saile B; Scharf JG; Ramadori G
Histochem Cell Biol; 2000 Jun; 113(6):443-53. PubMed ID: 10933221
[TBL] [Abstract][Full Text] [Related]
14. Differential gene expression of extracellular matrix components in dilated cardiomyopathy.
Tyagi SC; Kumar S; Voelker DJ; Reddy HK; Janicki JS; Curtis JJ
J Cell Biochem; 1996 Nov; 63(2):185-98. PubMed ID: 8913870
[TBL] [Abstract][Full Text] [Related]
15. Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients.
Picard F; Brehm M; Fassbach M; Pelzer B; Scheuring S; Küry P; Strauer BE; Schwartzkopff B
Clin Res Cardiol; 2006 May; 95(5):261-9. PubMed ID: 16598395
[TBL] [Abstract][Full Text] [Related]
16. Association of matrix metalloproteinase expression and left ventricular function in idiopathic dilated cardiomyopathy.
Yokoseki O; Yazaki Y; Suzuki J; Imamura H; Takenaka H; Isobe M
Jpn Circ J; 2000 May; 64(5):352-7. PubMed ID: 10834450
[TBL] [Abstract][Full Text] [Related]
17. Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodelling.
Wei Y; Cui C; Lainscak M; Zhang X; Li J; Huang J; Zhang H; Zheng Z; Hu S
J Cell Mol Med; 2011 Apr; 15(4):773-82. PubMed ID: 20219015
[TBL] [Abstract][Full Text] [Related]
18. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.
Spinale FG; Coker ML; Bond BR; Zellner JL
Cardiovasc Res; 2000 May; 46(2):225-38. PubMed ID: 10773226
[TBL] [Abstract][Full Text] [Related]
19. MMP and TIMP expression pattern in pleural effusions of different origins.
Eickelberg O; Sommerfeld CO; Wyser C; Tamm M; Reichenberger F; Bardin PG; Solèr M; Roth M; Perruchoud AP
Am J Respir Crit Care Med; 1997 Dec; 156(6):1987-92. PubMed ID: 9412584
[TBL] [Abstract][Full Text] [Related]
20. Secretion of matrix metalloproteinase-2 (72 kD gelatinase/type IV collagenase = gelatinase A) by malignant human glioma cell lines: implications for the growth and cellular invasion of the extracellular matrix.
Nakagawa T; Kubota T; Kabuto M; Fujimoto N; Okada Y
J Neurooncol; 1996 Apr; 28(1):13-24. PubMed ID: 8740587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
